How Would You Like to Have an Orchidectomy for Advanced Prostatic Cancer?

Surgical orchidectomy is a simple procedure with few physical side effects, low mortality, and cost effectiveness. Nevertheless, there can be negative sequelae such as sexual dysfunction, impaired quality of life, and poor body image. Although it is a frequent treatment approach for prostate cancer, it is not clear whether these sequelae are problematic for this patient group. It is possible that relief from painful metastases and the prolongation of life outweigh these negative factors. The present study investigated quality of life, sex-role identity, and sexual function in 15 patients with stage D prostate cancer, before and after surgery. Orchidectomy did not appear to affect quality of life, or sex-role identity. However, loss of sexual function did present as an area of concern. It was noted that 55% of premorbidly sexually active patients found this loss disturbing. These patients, premorbidly, appeared to have higher sex-role stereotypy.

show abstract

“…reported loss of function after surgery. This loss of function had been expected and is well documented in the literature (2,12).…”

Section: Resultssupporting

confidence: 70%

Quality of Life, Sexual Functioning and Sex Role Identity After Surgical Orchidectomy in Patients with Prostatic Cancer

Lucas

Strijdom

Berk

et al. 1995

Scandinavian Journal of Urology and Nephrology

View full text Add to dashboard Cite

show abstract

“…During recent years, quality of life (QL) has increasingly become the focus of interest in clinical cancer trials [3,5,11,14,16,19,20,22,24,31]. The methodology of QL evaluation is, however, an ongoing issue of debate [1, 10,28,29].…”

Section: Introductionmentioning

confidence: 99%

Patients' and doctors' perception of long-term morbidity in patients with testicular cancer clinical stage I

Fosså

Moynihan

Serbouti

1996

Support Care Cancer

View full text Add to dashboard Cite

Patient-based questionnaires were designed with the aim to identify and rank long-term somatic and psychosocial morbidity in patients with low-stage testicular cancer. A further intention was to compare patients' assessments with experienced doctors' general opinion on quality of life items in cured testicular cancer patients. In pilot study I, 103 tumour-free patients ranked items of physical and psychosocial morbidity after having had various kinds of treatment. Though the ranking procedure appeared to cause some difficulties amongst the patients and subsequently was abandoned, the results indicated considerable differences between the patients' and doctors' evaluations. In pilot study II patients were asked to score the different items. The questionnaire of pilot study II was completed by 107 patients from the Norwegian Radium Hospital (NRH) and 99 relapse-free patients from the Royal Marsden Hospital (RMH) with testicular cancer stage I at least 1 year after infradiaphragmatic radiotherapy (n = 94) or adjuvant chemotherapy (2 cycles, n = 26), or patients who had been followed on the surveillance program (n = 86). A total of 93 doctors completed a similar questionnaire, thereby expressing their general opinion on long-term morbidity in comparable testicular cancer patients as seen during routine clinical follow-up. Both the irradiated patients and those on the surveillance program reported slight degrees of Raynaud-like phenomena, neurotoxicity and ototoxicity, most probably representing "background morbidity" in an age-matched general male population. Doctors tended to underestimate their patients' somatic morbidity, but often overestimated the degree of psychological distress, in particular in patients on the surveillance program. Significant differences between RMH and NRH patients with regard to sexual problems and to leisure time activity may be explained by cultural differences in the two countries. The items presented in the questionnaire used identify important issues for patients cured of testicular cancer which may be used in future multicentre trans-cultural studies assessing these patients' quality of life. This will provide sufficient data for psychometric testing and, together with the findings from patients' free comments, support the final design of a testicular cancer quality of life module.

show abstract

“…An initial plasma peak of the agonist in the first few hours after injection is followed by a decrease in plasma levels over 10 hours, eventually displaying a plateau level for 28 days. Testosterone levels initially increase, then decrease to lower than the castration level and persist that way for a month [16,17]. Present depot formulations of triptorelin and leuprolide in microcapsules of poly(D,L-lactide-co-glycolide) for intramuscular injection are now available in forms that release the drug over 3 to 12 months [2,16].…”

Section: Lhrh Agonistsmentioning

confidence: 99%

Bench-to-bedside development of agonists and antagonists of luteinizing hormone–releasing hormone for treatment of advanced prostate cancer

Rick

Schally

2015

Urologic Oncology: Seminars and Original Investigations

View full text Add to dashboard Cite

How Would You Like to Have an Orchidectomy for Advanced Prostatic Cancer?

Cited by 19 publications

References 0 publications

Quality of Life, Sexual Functioning and Sex Role Identity After Surgical Orchidectomy in Patients with Prostatic Cancer

Quality of Life, Sexual Functioning and Sex Role Identity After Surgical Orchidectomy in Patients with Prostatic Cancer

Patients' and doctors' perception of long-term morbidity in patients with testicular cancer clinical stage I

Bench-to-bedside development of agonists and antagonists of luteinizing hormone–releasing hormone for treatment of advanced prostate cancer

Contact Info

Product

Resources

About